Trial · NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945, Phase 1, Phase 2, Recruiting, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma. Trials, record NCT06106945. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06106945
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- NCT number
- NCT06106945
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 226 participants, estimated
- Lead sponsor
- AstraZeneca
- Conditions
- Multiple Myeloma
- Interventions
- AZD0305, Elranatamab, Pomalidomide, Dexamethasone
- First posted
- 2023-10-30
- Last updated
- 2026-10-30
Source ClinicalTrials.gov
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only) | From first dose of AZD0305 until the end of Cycle 1. Cycle 1 (the DLT assessment period is 21 days for Module 1 Group A and 28 days for Module 1 Group B, Module 2, and Module 3) | A DLT is any toxicity occuring from the first dose of AZD0305 up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation and which includes, any death not clearly due to the underlying disease or extraneous causes, pre-defined haematological and non-haematological toxicities |
| Primary | Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | From time of Informed consent to 30 days post end of treatment | Number of patients with adverse events and serious adverse events by system organ class and preferred term |
| Primary | Frequency of dose modifications, dose delays, and treatment discontinuations due to AEs (Module 2 and Module 3) | From first dose of study treatment until End of treatment (EOT), assessed up to approximately 2 years (each cycle is 28 days) | Number and percentage of participants with dose modifications, dose delays, and permanent discontinuations due to adverse events (for AZD0305 and combination agent\[s\], as applicable), per protocol-defined dose modification rules. |
| Secondary | Phase Ia: Objective Response Rate (ORR) | From first dose of AZD0305 to progressive disease or Initiation of subsequent MM therapy (approximately 2 years) | The percentage of patients with a confirmed investigator assessed sCR, CR, VGPR or PR according to IMWG criteria |
| Secondary | Phase Ia: Duration of response (DoR) | From the first documented response to confirmed progressive disease or death (approximately 2 years) | The time from the date of first response until date of disease progression or death in the absence of disease progression |
| Secondary | Phase Ia: Progression free Survival (PFS) | From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years) | The time from first dose until IMWG defined disease progression or death |
| Secondary | Phase Ia: Overall Survival (OS) | From first dose of AZD0305 to death (approximately 2 years) | The time from the date of the first dose of study treatment until death due to any cause |
| Secondary | Phase Ia: Pharmacokinetics of AZD0305: Area Under the concentration-time curve (AUC) | From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years) | Area under the plasma concentration-time curve |
| Secondary | Phase Ia: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax) | From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years) | Maximum observed plasma concentration of the study drug |
| Secondary | Phase Ia: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax) | From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years) | Time to maximum observed plasma concentration of the study drug |
1 to 10 of 29Source ClinicalTrials.gov
See all 29 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06106945
GET https://conductscience.org/api/trials/v1/NCT06106945/registered?page=2